Feng Yang, Dimitrov Dimiter S
Protein Interactions Group, Nanobiology Program, CCR, NCI-Frederick, NIH, Bldg 469, Rm 139, Frederick, MD 21702-1201, USA.
Curr Opin Drug Discov Devel. 2008 Mar;11(2):178-85.
Insulin-like growth factor (IGF)-mediated signaling pathways have long been recognized as important targets for cancer therapy. The development of antibodies against the IGF type I receptor (IGF-IR) started in the early 1980s, although clinical studies of these antibodies were not conducted until more recent years. At least eight different anti-IGF-IR antibodies are currently in clinical trials and are reviewed in this article; each antibody was generated by a different method and has unique features. Information collected from these early clinical trials should be taken into consideration during the design of further studies and future clinical applications, as well as in the improvement of the respective antibodies. The development of antibodies against IGF ligands is also discussed.
胰岛素样生长因子（IGF）介导的信号通路长期以来一直被认为是癌症治疗的重要靶点。针对I型胰岛素样生长因子受体（IGF-IR）的抗体研发始于20世纪80年代初，不过这些抗体的临床研究直到近年来才开展。目前至少有八种不同的抗IGF-IR抗体正在进行临床试验，本文将对其进行综述；每种抗体都是通过不同方法产生的，具有独特的特性。在设计进一步的研究和未来的临床应用时，以及在改进各抗体的过程中，都应考虑从这些早期临床试验中收集到的信息。本文还讨论了针对IGF配体的抗体的研发情况。
